Congestive heart failure left ventricular assist devices: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (5 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{| class="infobox" style="float:right;" | |||
|- | |||
| [[File:Siren.gif|30px|link= Congestive heart failure resident survival guide]]|| <br> || <br> | |||
| [[Acute decompensated heart failure resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | |||
|} | |||
{| class="infobox" style="float:right;" | |||
|- | |||
| [[File:Critical_Pathways.gif|88px|link= Congestive heart failure critical pathways]]|| <br> || <br> | |||
|} | |||
{{Congestive heart failure}} | {{Congestive heart failure}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{EdzelCo}} | ||
==Overview== | ==Overview== | ||
[[Left ventricular assist device]]s ([[LVADs]]) are temporary implantable cardiac devices to sustain a patient (i.e. "bridge" the patient) until [[cardiac transplantation]] can be performed. The use of LVADs as a "destination" device (the final treatment) rather than as a bridge is investigational at present. | [[Left ventricular assist device]]s ([[LVADs]]) are temporary implantable cardiac devices to sustain a patient (i.e. "bridge" the patient) until [[cardiac transplantation]] can be performed. The use of LVADs as a "destination" device (the final treatment) rather than as a bridge is investigational at present. | ||
==Wearables and Remote Monitoring (Including Telemonitoring and Device Monitoring) 2022 AHA/ACC/HFSA Heart Failure Guideline (DO NOT EDIT) <ref name="pmid35363500">{{cite journal| author=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM | display-authors=etal| title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2022 | volume= 145 | issue= 18 | pages= e876-e894 | pmid=35363500 | doi=10.1161/CIR.0000000000001062 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=35363500 }} </ref> == | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | |||
|- | |||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' In selected [[adult]] [[patients]] with [[NYHA]] class III [[HF]] and history of a [[HF]] [[hospitalization]] in the past year or elevated [[natriuretic peptide]] levels, on maximally tolerated stable [[doses]] of [[GDMT]] with optimal [[device therapy]], the usefulness of wireless monitoring of [[PA pressure]] by an implanted [[hemodynamic]] monitor to reduce the risk of subsequent [[HF]] [[hospitalization]] is uncertain. <ref name="pmid21315441">{{cite journal| author=Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW | display-authors=etal| title=Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. | journal=Lancet | year= 2011 | volume= 377 | issue= 9766 | pages= 658-66 | pmid=21315441 | doi=10.1016/S0140-6736(11)60101-3 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21315441 }} </ref><ref name="pmid25286913">{{cite journal| author=Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C | display-authors=etal| title=Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. | journal=Circ Heart Fail | year= 2014 | volume= 7 | issue= 6 | pages= 935-44 | pmid=25286913 | doi=10.1161/CIRCHEARTFAILURE.113.001229 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25286913 }} </ref><ref name="pmid28982501">{{cite journal| author=Givertz MM, Stevenson LW, Costanzo MR, Bourge RC, Bauman JG, Ginn G | display-authors=etal| title=Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. | journal=J Am Coll Cardiol | year= 2017 | volume= 70 | issue= 15 | pages= 1875-1886 | pmid=28982501 | doi=10.1016/j.jacc.2017.08.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28982501 }} </ref><ref name="pmid34461042">{{cite journal| author=Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D | display-authors=etal| title=Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. | journal=Lancet | year= 2021 | volume= 398 | issue= 10304 | pages= 991-1001 | pmid=34461042 | doi=10.1016/S0140-6736(21)01754-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34461042 }} </ref>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-R]])'' <nowiki>"</nowiki> | |||
|} | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:White"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Value Statement: Uncertain Value]] | |||
|- | |||
| bgcolor="White"|<nowiki>"</nowiki>'''1.''' In [[patients]] with [[NYHA]] class III [[HF]] with a [[HF]] [[hospitalization]] within the previous year, wireless monitoring of the [[PA pressure]] by an implanted [[hemodynamic]] monitor provides uncertain value. <ref name="pmid34461042">{{cite journal| author=Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D | display-authors=etal| title=Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. | journal=Lancet | year= 2021 | volume= 398 | issue= 10304 | pages= 991-1001 | pmid=34461042 | doi=10.1016/S0140-6736(21)01754-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34461042 }} </ref><ref name="pmid27647784">{{cite journal| author=Martinson M, Bharmi R, Dalal N, Abraham WT, Adamson PB| title=Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial. | journal=Eur J Heart Fail | year= 2017 | volume= 19 | issue= 5 | pages= 652-660 | pmid=27647784 | doi=10.1002/ejhf.642 | pmc=5434920 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27647784 }} </ref><ref name="pmid26874380">{{cite journal| author=Sandhu AT, Goldhaber-Fiebert JD, Owens DK, Turakhia MP, Kaiser DW, Heidenreich PA| title=Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure. | journal=JACC Heart Fail | year= 2016 | volume= 4 | issue= 5 | pages= 368-75 | pmid=26874380 | doi=10.1016/j.jchf.2015.12.015 | pmc=4851610 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26874380 }} </ref><ref name="pmid28272808">{{cite journal| author=Schmier JK, Ong KL, Fonarow GC| title=Cost-Effectiveness of Remote Cardiac Monitoring With the CardioMEMS Heart Failure System. | journal=Clin Cardiol | year= 2017 | volume= 40 | issue= 7 | pages= 430-436 | pmid=28272808 | doi=10.1002/clc.22696 | pmc=6490396 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28272808 }} </ref>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR]])'' <nowiki>"</nowiki> | |||
|} | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Cardiology]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Intensive care medicine]] | |||
[[Category:Medicine]] | |||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Up-To-Date cardiology]] | [[Category:Up-To-Date cardiology]] | ||
Latest revision as of 23:50, 22 June 2022
 |
Resident Survival Guide |
| File:Critical Pathways.gif |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Edzel Lorraine Co, DMD, MD[2]
Overview
Left ventricular assist devices (LVADs) are temporary implantable cardiac devices to sustain a patient (i.e. "bridge" the patient) until cardiac transplantation can be performed. The use of LVADs as a "destination" device (the final treatment) rather than as a bridge is investigational at present.
Wearables and Remote Monitoring (Including Telemonitoring and Device Monitoring) 2022 AHA/ACC/HFSA Heart Failure Guideline (DO NOT EDIT) [1]
| Class IIb |
| "1. In selected adult patients with NYHA class III HF and history of a HF hospitalization in the past year or elevated natriuretic peptide levels, on maximally tolerated stable doses of GDMT with optimal device therapy, the usefulness of wireless monitoring of PA pressure by an implanted hemodynamic monitor to reduce the risk of subsequent HF hospitalization is uncertain. [2][3][4][5](Level of Evidence: B-R) " |
| Value Statement: Uncertain Value |
| "1. In patients with NYHA class III HF with a HF hospitalization within the previous year, wireless monitoring of the PA pressure by an implanted hemodynamic monitor provides uncertain value. [5][6][7][8](Level of Evidence: B-NR) " |
References
- ↑ Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM; et al. (2022). "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 145 (18): e876–e894. doi:10.1161/CIR.0000000000001062. PMID 35363500 Check
|pmid=value (help). - ↑ Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW; et al. (2011). "Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial". Lancet. 377 (9766): 658–66. doi:10.1016/S0140-6736(11)60101-3. PMID 21315441.
- ↑ Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C; et al. (2014). "Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction". Circ Heart Fail. 7 (6): 935–44. doi:10.1161/CIRCHEARTFAILURE.113.001229. PMID 25286913.
- ↑ Givertz MM, Stevenson LW, Costanzo MR, Bourge RC, Bauman JG, Ginn G; et al. (2017). "Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction". J Am Coll Cardiol. 70 (15): 1875–1886. doi:10.1016/j.jacc.2017.08.010. PMID 28982501.
- ↑ 5.0 5.1 Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D; et al. (2021). "Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial". Lancet. 398 (10304): 991–1001. doi:10.1016/S0140-6736(21)01754-2. PMID 34461042 Check
|pmid=value (help). - ↑ Martinson M, Bharmi R, Dalal N, Abraham WT, Adamson PB (2017). "Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial". Eur J Heart Fail. 19 (5): 652–660. doi:10.1002/ejhf.642. PMC 5434920. PMID 27647784.
- ↑ Sandhu AT, Goldhaber-Fiebert JD, Owens DK, Turakhia MP, Kaiser DW, Heidenreich PA (2016). "Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure". JACC Heart Fail. 4 (5): 368–75. doi:10.1016/j.jchf.2015.12.015. PMC 4851610. PMID 26874380.
- ↑ Schmier JK, Ong KL, Fonarow GC (2017). "Cost-Effectiveness of Remote Cardiac Monitoring With the CardioMEMS Heart Failure System". Clin Cardiol. 40 (7): 430–436. doi:10.1002/clc.22696. PMC 6490396. PMID 28272808.